Literature DB >> 2758539

Cumulative dose-response curves for atracurium in patients with myasthenia gravis.

C E Smith1, F Donati, D R Bevan.   

Abstract

The potency of atracurium was determined in five patients with moderate to severe generalized myasthenia gravis undergoing thymectomy. Train-of-four stimulation was applied to the ulnar nerve and the force of contraction of the adductor pollicis was measured. Cumulative dose-response curves were obtained during thiopentone-nitrous oxide-fentanyl anaesthesia. The average time to complete the dose-response studies was 12.7 +/- 1.5 minutes. The ED50, ED90 and ED95 of atracurium were (mean +/- SEM) 0.07 +/- 0.01, 0.12 +/- 0.22, and 0.14 +/- 0.04 mg.kg-1, respectively. The time to 25 per cent first twitch recovery was 35 +/- 4 min following maximum blockade. Ten normal patients were studied in the same manner. Their ED50, ED90 and ED95 were 0.13 +/- 0.01, 0.21 +/- 0.02 and 0.24 +/- 0.03 mg.kg-1, respectively. These results demonstrated that, in patients with moderate to severe generalized myasthenia gravis, atracurium was 1.7-1.9 times as potent as in normal individuals.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2758539     DOI: 10.1007/BF03005338

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  30 in total

Review 1.  Myasthenia gravis (first of two parts).

Authors:  D B Drachman
Journal:  N Engl J Med       Date:  1978-01-19       Impact factor: 91.245

2.  The response of myasthenia gravis to atracurium.

Authors:  C A Vacanti; H H Ali; J F Schweiss; R P Scott
Journal:  Anesthesiology       Date:  1985-05       Impact factor: 7.892

3.  Drug-receptor reactions.

Authors:  J Norman
Journal:  Br J Anaesth       Date:  1979-07       Impact factor: 9.166

4.  Cumulative dose-response with infusion: a technique to determine neuromuscular blocking potency of atracurium and vecuronium.

Authors:  C E Smith; F Donati; D R Bevan
Journal:  Clin Pharmacol Ther       Date:  1988-07       Impact factor: 6.875

5.  Potency of atracurium: a comparison of single dose and cumulative dose techniques.

Authors:  F M Gibson; R K Mirakhur; G G Lavery; R S Clarke
Journal:  Anesthesiology       Date:  1985-05       Impact factor: 7.892

6.  Human dose-response curves for neuromuscular blocking drugs: a comparison of two methods of construction and analysis.

Authors:  J V Donlon; J J Savarese; H H Ali; R S Teplik
Journal:  Anesthesiology       Date:  1980-08       Impact factor: 7.892

Review 7.  Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients.

Authors:  K E Osserman; G Genkins
Journal:  Mt Sinai J Med       Date:  1971 Nov-Dec

8.  Neuromuscular blockade in myasthenia gravis with atracurium besylate.

Authors:  S Ward; D J Wright
Journal:  Anaesthesia       Date:  1984-01       Impact factor: 6.955

9.  Clinical use of atracurium in myasthenia gravis: a case report.

Authors:  F M Ramsey; G D Smith
Journal:  Can Anaesth Soc J       Date:  1985-11

10.  Ultrastructural localization of the acetylcholine receptor in myasthenia gravis and in its experimental autoimmune model.

Authors:  A G Engel; J M Lindstrom; E H Lambert; V A Lennon
Journal:  Neurology       Date:  1977-04       Impact factor: 9.910

View more
  2 in total

Review 1.  Anaesthesia and myasthenia gravis.

Authors:  A Baraka
Journal:  Can J Anaesth       Date:  1992-05       Impact factor: 5.063

Review 2.  Perioperative Management of Neurological Conditions.

Authors:  Manjeet Singh Dhallu; Ahmed Baiomi; Madhavi Biyyam; Sridhar Chilimuri
Journal:  Health Serv Insights       Date:  2017-06-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.